Tropical diseases

Massitan Dembélé and Yao Sodahlon Win 2020 Kyelem Prize

Retrieved on: 
Monday, November 16, 2020
Medical specialties, Infectious diseases, Health, Clinical medicine, Tropical diseases, Global health, Neglected tropical diseases, Sanitation, Sustainable Development Goal 6, NTD, Tropical disease

DECATUR, Ga., Nov. 16, 2020 /PRNewswire/ --Today at the annual meeting of the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), the Neglected Tropical Diseases Support Center announced Doctors Massitan Dembl and Yao Sodahlon as co-winners of the 2020 Kyelem Prize.

Key Points: 
  • DECATUR, Ga., Nov. 16, 2020 /PRNewswire/ --Today at the annual meeting of the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), the Neglected Tropical Diseases Support Center announced Doctors Massitan Dembl and Yao Sodahlon as co-winners of the 2020 Kyelem Prize.
  • The Kyelem Prize is named for the late Dr. Dominique Kyelem (1962-2013).
  • Massitan Dembl and Yao Sodahlon were selected by their peers as co-winners of the 2020 Kyelem Prize.
  • About the Kyelem Prize:The Kyelem Prize is given annually in honor of Dr. Dominique Kyelem at the COR-NTD meeting.

Victory Square Technologies Portfolio Company’s Leishmaniasis Rapid Test Receives Brazilian MAPA Approval for Sale & Use for the Country of Brazil and Enters into a Sales & Distribution Contract with Ecodiagnostica of Brazil

Retrieved on: 
Friday, November 13, 2020
Infectious diseases, Medical specialties, Trypanosomatida, Neglected tropical diseases, Tropical diseases, Zoonoses, Leishmaniasis, Leishmania, Visceral leishmaniasis

The Company entered into a sales & distribution contract and formal partnership for the Leishmaniasis test with Ecodiagnostica of Brazil.

Key Points: 
  • The Company entered into a sales & distribution contract and formal partnership for the Leishmaniasis test with Ecodiagnostica of Brazil.
  • Leishmaniasis is a parasitic disease that affects humans and canines in Southern Europe, Central America, South America, Mexico and the Middle East.
  • [3] [11]
    The Company is pleased to have entered into a partnership, sales and distribution contract with Ecodiagnostica of Brazil for the sale of the Leishmaniasis test for South America.
  • Founded in 2012, Ecodiagnostica is based in Nova Lima, Brazil and has extensive sales and distribution networks across South America and beyond.

Global WholeHealth Partners Corp. (GWHP) Announces It Now Offers the New FDA Cleared Fingerstick for Rapid COVID-19 Test Results in Minutes

Retrieved on: 
Thursday, November 5, 2020
Infectious diseases, Medical specialties, Medicine, Tropical diseases, Zoonoses, Vaccine-preventable diseases, Medical terminology, Medical tests, Ebola, Rapid diagnostic test, Malaria, Fingerstick

With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.

Key Points: 
  • With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.
  • On September 23, 2020, that EUA was being reissued to authorize the test for POC use using fingerstick blood samples.
  • 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.
  • 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.

Rift Valley fever: surveillance measures assessed

Retrieved on: 
Wednesday, November 4, 2020
Infectious diseases, Medical specialties, Tropical diseases, Neglected tropical diseases, Clinical medicine, Biological weapons, Rift Valley fever, Zoonoses, RVF, Mosquito, 2006–07 East Africa Rift Valley fever outbreak

EFSA has completed its series of assessments on Rift Valley fever (RVF) with a scientific opinion looking at the effectiveness of surveillance and control measures in the EU.

Key Points: 
  • EFSA has completed its series of assessments on Rift Valley fever (RVF) with a scientific opinion looking at the effectiveness of surveillance and control measures in the EU.
  • The latest opinion follows two opinions published earlier this year which assessed respectively the risk of introduction of RVF to the EU and the impact of the disease in the French overseas department of Mayotte.
  • Background

    Rift Valley fever is a vector-borne disease transmitted by mosquitoes to animals domestic and wild ruminants and camels and humans.

  • In 2018-19 it reappeared after ten years in Mayotte, where there have been outbreaks involving multiple human cases.

Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Retrieved on: 
Thursday, October 22, 2020
Other Consumer, Infectious diseases, Clinical trials, Philanthropy, Biotechnology, Pharmaceutical, Consumer, Health, Foundation, Other Philanthropy, Infectious diseases, Medical specialties, Medicine, RTT, Neglected tropical diseases, Tropical diseases, Helminthiases, Spirurida, Onchocerciasis, Lymphatic filariasis, Ivermectin, Filariasis, Merck, the MECTIZAN® Donation Program

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).
  • The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases.
  • After months of careful assessment, in July, WHO released a decision-making framework for resuming MDA during the ongoing pandemic.
  • The SARS-CoV-2 pandemic is especially challenging for communities that continue to be threatened by river blindness and lymphatic filariasis.

Key patent granted for Isla101 in Brazil

Retrieved on: 
Monday, October 19, 2020
Infectious diseases, Medical specialties, Tropical diseases, Medicine, Dengue fever, Myelitis, Zoonoses, Mosquito, Patent

Isla101, a drug with a well understood safety profile, is being repurposed for the potential prevention and treatment of mosquito borne diseases.

Key Points: 
  • Isla101, a drug with a well understood safety profile, is being repurposed for the potential prevention and treatment of mosquito borne diseases.
  • Having an allowed patent that protects Isla's lead program in this large market provides protection for the development of Isla101 and allows the Company to advance the program in Brazil, which is one of our key target markets."
  • Brazil generally has the greatest number of dengue cases in the world, with more than 2 million cases 2019 alone.
  • The Brazilian patent grant was issued on 29 September 2020 by the Brazilian Industrial Property Office, under the Brazil Patent No BR 112015026243-0.

FDA Approves First Treatment for Ebola Virus

Retrieved on: 
Wednesday, October 14, 2020
Medical specialties, Medicine, Infectious diseases, Biological weapons, Tropical diseases, Zoonoses, West African Ebola virus epidemic, Ebola, Zaire ebolavirus, rVSV-ZEBOV vaccine, Ebola vaccine, Science diplomacy and pandemics

Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease.

Key Points: 
  • Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease.
  • Individuals who provide care for people with Ebola virus, including health care workers who do not use correct infection control precautions, are at the highest risk for infection.
  • Inmazeb received an Orphan Drug designation for the treatment of Ebola virus infection.
  • The FDA approved Ervebo, the first vaccine for the prevention of Ebola virus disease, in December 2019, with support from a study conducted in Guinea during the 2014-2016 Ebola outbreak.

Chloroquine Market | Increasing Prevalence of Malaria to Boost the Market Growth | Technavio

Retrieved on: 
Saturday, October 10, 2020
Infectious diseases, Pharmaceutical, Health, Infectious diseases, Medical specialties, RTT, Clinical medicine, Chloroarenes, Quinolines, Tropical diseases, Chloroquine, Malaria, Mass drug administration, Antimalarial medication

Thus, the increasing prevalence of malaria will drive the growth of the chloroquine market.

Key Points: 
  • Thus, the increasing prevalence of malaria will drive the growth of the chloroquine market.
  • The high prevalence rate of malaria, increasing awareness about the treatment options for malaria, and strong funding by governments and private organizations to eradicate malaria are the main factors driving the growth of the chloroquine market in the malaria segment.
  • To help clients improve their market position, this chloroquine market forecast report provides a detailed analysis of the market leaders.
  • The growing demand across the world and increasing production of chloroquine by key vendors will boost the growth of the global chloroquine market during the forecast period.

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Retrieved on: 
Friday, October 9, 2020
Medical specialties, Clinical medicine, Infectious diseases, Neglected tropical diseases, Vaccination, Tropical diseases, Priority review, Vaccine, Rabies, Immunotherapy

IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines.

Key Points: 
  • IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines.
  • Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged, and their value has increased.
  • Our goal at MABT is to provide the first viable treatment option for patients suffering from advanced rabies disease, using our novel IMT504 immunotherapy platform.
  • About Connectyx Technologies Holdings Group, Inc. http://connectyx.com/
    Connectyxis a development-stage biomedical company focusing on novel treatments for rare diseases.

NLR launches innovative research project to end leprosy transmission in India

Retrieved on: 
Monday, October 5, 2020
Infectious diseases, Medical specialties, Tropical diseases, Leprosy, RTT, Clinical medicine, Lepra

AMSTERDAM, Oct. 5, 2020 /PRNewswire/ -- NLR and NLR India hosted the official start of the innovative project 'Stop the Transmission of Leprosy!'

Key Points: 
  • AMSTERDAM, Oct. 5, 2020 /PRNewswire/ -- NLR and NLR India hosted the official start of the innovative project 'Stop the Transmission of Leprosy!'
  • Project , focuses on early detection of leprosy and preventive treatment of people who have frequent and close contact with persons affected by leprosy.
  • Theproject, designed by NLR in collaboration with national stakeholders, aims to stop the transmission of leprosy by using a package of innovative tools and best practices.
  • NLR takes pride in enabling research and driving evidence-based innovation to achieve zero transmission, zero disability and zero discrimination due to leprosy.